Iantech | Addressing the world’s biggest vision need
21614
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-21614,ajax_fade,page_not_loaded,,select-child-theme-ver-1.0.0,select-theme-ver-3.7,wpb-js-composer js-comp-ver-5.2.1,vc_responsive

Iantech’s technology

 

After 50 years of conventional phacoemulsification, Iantech introduces a micro-­interventional devices designed to deliver energy-­free endocapsular lens fragmentation. At Iantech, we are working to invent new surgical approaches designed to address the global footprint of cataract blindness. Using smart, efficient and adaptable micro-­interventional technology, our team is building a new surgical platform.

Watch miLOOP unveiling at the ASCRS Congress:

Innovation talk by Dr. Ianchulev

ianTECH innovation

Introducing the miLOOP™ Lens Fragmentation Device

Micro­stents and MIGS intervention have already changed the paradigm of glaucoma treatment. Iantech has taken micro-­interventional technology by applying advanced micro-­engineered memory ­shaped materials and instrumentation for mechanical, energy-independent cataract disassembly. The miLOOP™ Device is the first in a line of ophthalmic tools engineered by Iantech for its micro­-interventional cataract surgery platform. Using micro­-thin super­-elastic, self ­expanding nitinol filament technology, the miLOOP™ device is designed to offer cataract surgeons the ability to achieve full ­thickness lens fragmentation for any grade cataract minimizing the intraocular ultrasonic vibrations and phaco power. Using micro­-thin super­-elastic, self ­expanding nitinol filament technology, miLOOP™ offers cataract surgeons the potential to achieve full ­thickness lens fragmentation for any grade cataract minimizing the intraocular application of ultrasonic vibrations and phaco power to the delicate ocular tissues.

Why miLOOP?

 

The miLOOP™ device is designed to achieve full-thickness fragmentation of the nucleus independent of phaco energy using a super-elastic thin-filament. It is engineered to minimize capsular stress by using centripetal, out-in nucleus disassembly while conventional techniques employ centrifugal, in-out lens cutting with adjunct phaco-energy. The miLOOP™ lens fragmentation is done under full viscoelastic chamber stability protection and no simultaneous irrigation and aspiration.

miLoop testimonials

miLOOP allows me to fragment the lens making my phaco technique easier” - Bill Trattler, MD
miLOOP allows me to fully fragment the lens with a peripheral approach, gently sweeping the cortex away from the capsule and disengaging the lens segments from the periphery, making them more accessible during phaco” – Jason Jones, MD
miLOOP exceeded my expectations… we evaluate a lot of technologies, and most do not exceed expectations… Now that I know what miLOOP can do for certain segments of my patients, it is an indispensable part of my surgical toolbox” – John Berdahl, MD
I was impressed with miLOOP’s ease of use and its possible disruptive potential in our space” – Bill Wiley, MD

individual results may vary

miPHACO surgical procedure

 

The miLOOP™ device is a micro-interventional instrument, which is designed to work in harmony with conventional phaco techniques for a more synergistic cataract procedure. The miLOOP device plus standard phaco = miPHACO surgical procedure

 

Explore our video library to learn more about the miLOOP™!

miMISSIONS

 

The miLOOP™ device is engineered to assist global outreach and humanitarian cataract efforts. Micro-interventional pen-like device is designed to support efforts to erase global blindness and to positively impact public health efforts in the 25 million blindness epidemic worldwide.

Dr. MacDonald and Dr. Ianchulev have pioneered the first miLOOP™ device missions in Panama and Tanzania. A new miLOOP™ device technique uses a no stitch 4mm scleral tunnel and is adoptable by cataract surgeons worldwide for sustainable global outreach!
Green box data: average long-term loss of corneal endothelium due to phaco surgery

 

Dr. MacDonald and Dr. Ianchulev have pioneered the first miLOOP™ missions in Panama and Tanzania. A new miLOOP™ technique with a 4mm scleral tunnel can not only make cataract surgery minimally invasive with improved clinical outcomes but can train cataract surgeons worldwide for sustainable global outreach!

25 mil

people blind from advanced cataracts

239 mil

Visually impaired

50%

of global blindness is from untreated cataracts

25%+

average loss of corneal endothelium due to phaco surgery

miTEAM

The Iantech Team has been at the center of breakthrough innovation in ophthalmology and has helped bring to life some of the greatest ophthalmic technologies over the last decade – with hundreds of thousands of patients benefiting every year – from Lucentis to intraoperative aberrometry to MIGS supraciliary stenting and now micro-interventional cataract surgery

Iantech Board

miSURGEONS

 

Micro-interventional phaco surgeons achieve superior outcomes in the most difficult cases using the breakthrough miLOOP™ device. The combined procedure of miLOOP™ nucleus disassembly and phaco-emulsification (aka miPHACO), was studied in a randomized controlled investigation (LEEP 103) comparing clinical outcomes and surgical efficiency to conventional phaco surgery. miPHACO with the miLOOP™ device statistically improved surgical performance with a significant reduction in burst phaco energy and fluidics delivered to the eye. The miLOOP™ device facilitated lens fragmentation, augmented cortical dissection and ultimately led to more efficient phacoemulsification.

For inquiries please email us at:

admin@iantechmed.com

Get in touch with a miLoop representative